February 13, 2019

Medexus Pharmaceuticals Schedules Third Quarter Fiscal 2019 Conference Call

Retains Crescendo Communications for Investor Relations Services

Conference call to be held at 4:30 PM Eastern Time on Monday, February 25, 2019

MONTREAL, Feb. 13, 2019 (GLOBE NEWSWIRE) -- **Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) (the "Company" or "Medexus") (TSXV: MDP, OTCQB: PDDPF)** today announced that it plans to host a conference call at 4:30 PM Eastern Time on Monday, February 25, 2019 to discuss the Company's financial results for the fiscal third quarter ended December 31, 2018, as well as the Company's corporate progress and other developments. The Company also announced it has retained Crescendo Communications, LLC ("Crescendo") to provide investor relations services for the Company.

Ken d'Entremont, Chief Executive Officer of Medexus, commented, "2018 was a transformative year for the Company, as we consummated the merger between Pediapharm Inc., Medexus Inc. and Medac Pharma, Inc. We are making rapid progress with the integration and look forward to working closely with Crescendo to more proactively communicate the market opportunity and commercial potential following this combination. Accordingly, we look forward to hosting quarterly conference calls with our investors going forward."

"As a result of the recent mergers, Medexus now operates through two segments, each with significant opportunities and substantial synergies. In addition to a robust product pipeline, we believe Medexus is well positioned in the market given the organic revenue growth, positive EBITDA, scalable infrastructure and solid balance sheet," noted David Waldman, CEO of Crescendo Communications. "We look forward to working closely with Medexus to help increase awareness of the Company within the U.S. investment community."

Conference Call Details

The conference call will be available via telephone by dialing toll free 866-682-6100 for Canadian and U.S. callers or +1 862-298-0702 for international callers, or on the Company's Investor Events section of the website: https://www.medexusinc.com/events/.

A webcast replay will be available on the Company's Investor Events section of the website (https://www.medexusinc.com/events/) through May 25, 2019. A telephone replay of the call will be available approximately one hour following the call, through March 4, 2019, and can be accessed by dialing 877-481-4010 for Canadian and U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 43906.

The investor relations services agreement with Crescendo (the "Agreement") is for an indeterminate term and may be terminated by Medexus at any time upon 30 days' notice.

Under the terms of the Agreement, Crescendo will provide, among other things, capital markets strategic advisory services and will assist the Company with market intelligence and investor targeting and events. Under the Agreement, Crescendo will receive a monthly fee of US$10,000 and eligible expenses will be reimbursed. The Agreement is subject to the approval of the TSX Venture Exchange.

About Medexus Pharmaceuticals Inc.

Medexus Pharmaceuticals Inc. is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company's vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.

For more information, please contact:

Ken d'Entremont, Chief Executive Officer
Medexus Pharmaceuticals Inc.
Tel.: 905-676-0003
E-mail: ken.dentremont@medexus.ca

Roland Boivin, Chief Financial Officer
Medexus Pharmaceuticals Inc.
Tel.: 514-762-2626 ext. 202
E-mail: roland.boivin@medexusinc.com

Investor Relations (U.S.):
Crescendo Communications, LLC
Tel: +1-212-671-1020
Email: ACST@crescendo-ir.com

Investor Relations (Canada):
Frank Candido
Direct Financial Strategies and Communication Inc.
Tel: 514-969-5530
E-mail: frank.candido@medexusinc.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

READER ADVISORIES
Forward Looking Statements
This press release contains "forward-looking information" within the meaning of applicable securities legislation. Forward-looking information includes, but is not limited to, statements with respect to future business operation and results. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or

anticipates will or may occur in the future are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the risk that the operations of the Company, Medac Pharma and Medexus will not be integrated successfully and the general risk that the Company's anticipated revenue growth and EBITDA will not meet current levels or future expectations, as well as other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Company can give no assurance that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature they involve inherent risks and uncertainties. The Company’s actual results, performance or achievement could differ materially from those expressed in, or implied by, the forward-looking information and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking information will transpire or occur, or if any of them do so, what benefits that Company will derive therefrom. Management has included the above summary of assumptions and risks related to forward-looking information provided in this press release in order to provide securityholders with a more complete perspective on the Company's future operations and such information may not be appropriate for other purposes. Readers should not place undue reliance on forward-looking statements. Readers are cautioned that the foregoing lists of factors are not exhaustive. Additional information on these and other factors that could affect the Company's operations or financial results are included in reports on file with applicable securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

NON-IFRS FINANCIAL MEASURES

The term EBITDA is used in this press release. The term EBITDA (earnings before interest, taxes, depreciation and amortization) does not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies. Rather, this measure is provided as additional information to complement IFRS measures by providing a further understanding of operations from management’s perspective. See the Company's management discussion and analysis and other reports on wile with applicable securities regulatory authorities accessible through the SEDAR website (www.sedar.com) for a further description of how the Company uses non-IFRS financial measures.

MEDEXUS PHARMA

Source: Medexus Pharmaceuticals Inc